SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eisai Says Lecanemab Slows Decline in Alzheimer’s Substudy

The report says lecanemab slowed decline among Alzheimer’s patients with alpha-synuclein co-pathology in a substudy.

BIIB

Related stories